MedTrace Logo

Safety, PK, and PD Comparison of UI059 and UIC202201 in Healthy Volunteers

NCT07727629 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-07-27

No results posted yet for this study

Summary

A randomized, open-label, multiple-dose, crossover phase 1 clinical trial to compare and evaluate the safety, pharmacokinetics and pharmacodynamics characteristics after oral administration of UI059 and UIC202201 in healthy adult volunteers

Conditions

  • Gastro Esophageal Reflux Disorder

Interventions

DRUG

UI059

take UI059 once a day for 7 days

DRUG

UIC202201

take UIC202201 once a day for 7 days

Sponsors & Collaborators

  • Korea United Pharm. Inc.

    lead INDUSTRY

Principal Investigators

  • Minkyu Park, MD, PhD · Chungbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07727629 on ClinicalTrials.gov